Model-informed optimization of COVID-19 therapies

• Ng TM*, Wang Z*, Chan EC. Physiologically‐based pharmacokinetic modelling guided dose evaluations of nirmatrelvir/ritonavir in renal impairment for the management of COVID‐19. British Journal of Clinical Pharmacology. 2024. 10.1111/bcp.16074

• Wang Z, Chan EC. Role of Cytochrome P450 2C8 in Drug–Drug Interaction between Amiodarone and Nirmatrelvir/Ritonavir Via Physiologically-Based Pharmacokinetic Modeling. Clinical Pharmacology & Therapeutics. 2023. 10.1002/cpt.2885

• Wang Z, Chan EC. Physiologically Based Pharmacokinetic Modelling-Guided Dose Management of Oral Anticoagulants when Initiating Paxlovid for COVID-19 Treatment. Clinical Pharmacology & Therapeutics. 2022. 10.1002/cpt.2687

  • Clinical Pharmacology & Therapeutics (Chinese Edition) 《临床药理学与治疗学》中文版. 2023. *https://mp.weixin.qq.com/s/eJZLUO2nqdMXpO3M_EgpDQ*

• Wang Z, Chan EC. Physiologically Based Pharmacokinetic Modelling to Investigate Baricitinib and Tofacitinib Dosing Recommendations for COVID‐19 in Geriatrics. Clinical Pharmacology & Therapeutics. 2022. 10.1002/cpt.2600

• Editorial highlighted

  van der Graaf PH. Diversity in Clinical Pharmacology Coming of Age. Clinical Pharmacology & Therapeutics. 2022. 10.1002/cpt.2680

• Related presentations

  • Online: 13th Annual Simcyp Virtual Seminar on Applications of Population-based IVIVE and PBPK, 2022.

  PBPK modelling for optimizing COVID-19 drug therapies: nirmatrelvir/ritonavir (Paxlovid) and baricitinib.

• Related press releases

  • NUS Science News

  Simulation technologies for optimising COVID-19 drug therapies

  • Medical Xpress

  Simulation technologies for optimizing COVID-19 drug therapies

Understanding of antithrombotic drugs

Anticoagulants

Warfarin

• Wang Z*, Xiang X*, …, Shin JG, Cai W. A physiologically based pharmacokinetic/pharmacodynamic modeling approach for drug-drug interaction evaluation of warfarin enantiomers with sorafenib. Drug Metabolism and Pharmacokinetics. 2021. 10.1016/j.dmpk.2020.10.001

• Related presentations

  • Guangzhou: The 4th Ling-Nan International Forum on DMPK, 2019.

  The use of mechanistic PBPK/PD modeling to assess pharmacodynamic changes of racemic drug interaction studies - warfarin as an example.

  • Portland: The 12th International ISSX Meeting, 2019.

  A Mechanistic PBPK/PD Modeling Approach to Predict the Effect of CYP3A4 on the Pharmacokinetics and Pharmacodynamics of Racemic Warfarin.

Rivaroxaban

• Wang Z, Chan ECY. Inhibition of cytochrome P450 2J2-mediated metabolism of rivaroxaban and arachidonic acid by ibrutinib and osimertinib. Drug Metabolism and Disposition, 2022. 10.1124/dmd.122.000928
  • Editor's choice articles for October 2022

American Society for Pharmacology and Experimental Therapeutics - ASPET on LinkedIn: #pharmacology

• Drug Metabolism and Disposition Highlighted Trainee Author for the October 2022 issue

Drug Metabolism and Disposition Highlighted Trainee Author for the October 2022 issue

• Wang Z, Cheong EJY, Kojodjojo P, Chan ECY. Model-Based Risk Prediction of Rivaroxaban with Amiodarone for Moderate Renal Impaired Elderly Population. Cardiovascular Drugs Therapy. 2023. 10.1007/s10557-021-07266-z